Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HA!! I'm really getting a kick out of Moby -- trying his hardest to sway all of the wavering investors!!! :)
M :)
Moby, sooooo... is that a "Yes"??
Jakedog,
Would your opinion change if Dr. Garnick is appointed to the BOD??
Many thanks!
"It's just hard for me to get excited that we're not in a death spiral downward right now when I just lost 80% of my shares."
Yea, but you must also remember that the price increased 80% as well.....
M :)
Hey Jake, didn't you decide to vote for the incentive plan?
I think credit is due to Ed Legere. He was an advocate for building the manufacturing side of the business, if it wasn't for his efforts Avid may never have existed.
Mark :)
"I know they have been installing larger and faster equipment and I would not be surprised to hear an announcement of plant expansion any day now."
Thanks for the response Dia -- I've been here for over 10 years now -- was a young man when I first invested in PPHM so hoping for the best now...
Mark :)
"There will be no "next year" third chance for big guys.
They want options this year, last chance to get rich."
I would think they'd be able to get rich on the options they have now -- If Bavi is as good as we think, I think we'll all be well-off, don't you??
Mark :)
Does the Avid facility have the capacity to handle that much workload????
Many thanks,
Mark :)
Hey realist, maybe you can chill a little on your eagerness to find any little negative thing in regards to PPHM. This is what happens when one is so eager to report bad news....
Mark :)
"Result: PPHM LARGER THAN ALL BP/BB PUT TOGETHER"
Slippery, how long do you estimate this to happen?
TIA,
Mark
"In other words it is a best case of MAYBE, and YEARS away in any case. "
I think stockpiling is more likely than your "maybe". The answer is a lot closer than you or others may think (not years, maybe months).
Mark :)
Flgfl4, thanks for your response --
Mark :)
Hi Flg4,
"Absolutely no way they have the capacity or the clients to generate the amount of PROFIT you're dreaming about."
I'm not sure that's correct. I recall back when Ed Legere was in charge, he was estimating the capacity to handle as much as 70 million in revs. Does anyone else remember this? CJ or Terry? I don't know why Ed's original estimate wouldn't apply now, especially since we've expanded capacity a couple of times since then.
Any thoughts??
Mark :)
I wonder where realist is? Seems to disappear whenever the pps rises, if pps drops later I bet we hear from him then!!
Hang in there longs!!
M :)
Last Today’s Change Bid Size Ask Size Volume
0.8734 +0.1235 (+16.47%) 0.8733 x2,000 0.8734 x3,800 2,994,114
Great analysis GeoCappy, agree with you 100% -- looks like my guess on getting a follow-up PR was correct.
M :)
My guess is we get another PR either tomorrow or Wednesday.
M :)
That is possible, however, I think the PR was well written, although most of its content was a rehash of what was already known. But the PFS info is new -- I'm just saying let's give it a chance to play through and then discuss the results later today. There's always a method and a reason for doing things a certain way, even if we investors don't agree.
M. :)
My take is that they are going to discuss the results from the 2nd cohort at 10:30am, then follow up witha PR afterward. Let's see what happens.
M :)
A snippet from the article:
" Peregrine is "in discussions with probably every big pharma company out there," Lytle said, but he added that the company believes data from its ongoing Phase II programs will increase the value of bavituximab."
Mark :)
Realist, what are you talking about? I don't ever recall Peregrine publishing an article like this one in the 1990's. Does anyone on this board know of similar articles published by Peregrine in the 1990's??
Mark :)
There are a couple of good articles in the November issue of Scientific American that discusses HIV. Brief mention of Anthony Fauci and the work he is doing in conjunction with the Bill and Melinda Gates Foundtion.
KT, is it possible the private investor is Ed Legere??
Does anyone know why they're truncating the Q&A portion of the conference calls? I'm pretty sure there were more than three people queued up to ask questions. In my opinion, not taking more calls indicates that they're hesitant to answer tough questions.
Would like to hear other opinions.
Many thanks,
Mark :)
I think there's more to it Tech. Something is going on and the BOD don't want to talk about it yet.
We'll soon see.....
Mark :)
Hello all!! Check out this article from the Orange County Business Journal. It mentions Peregrine and the fact Pergrine decline an interview request. I find it pretty interesting that they would decline an interview that could generate publicity.
Any thoughts?
Mark :)
Link: http://www.ocbj.com/industry_article_pay.asp?aID=76322682.4076199.1619137.63572602.3732677.070&aID2=124540
Economy Could Prompt More Small Drug Co. Buyouts
By Vita Reed
Orange County Business Journal Staff
Ista researcher: company considering acquisitions for growth
Ista researcher: company considering acquisitions for growth
The tough economy could open up deal opportunities for some of Orange County’s smaller drug and device companies.
There’s already been movement on that front, according to market watchers. Earlier this month, Irvine eye drug maker Ista Pharmaceuticals Inc. hired Cowen & Co. to evaluate opportunities that could include an acquisition and other business combinations.
Ista hired Cowen around the same time that it reported disappointing clinical results for a new version of its Xibrom eye inflammation-fighting drug, which accounts for 70% of its sales.
Earlier this year, Bausch & Lomb Inc. of Rochester, N.Y., bought Eyeonics Inc., an Aliso Viejo maker of replacement lenses used in cataract surgeries.
“It’s not surprising that we might hear rumors of smaller drug and device companies considering an M&A transaction,” said Dennis McCarthy, a managing director at B. Riley & Co., an investment bank with offices in Newport Beach and Los Angeles.
Several forces are driving demand, McCarthy said.
Potential buyers could look to deals to quickly grow revenue, he said.
And large healthcare companies have either cash on hand or ready access to cheap loans, “so the turmoil in the debt markets is not a deterrent to buy small drug and device companies,” McCarthy said.
Hospitals and smaller healthcare companies are feeling the turmoil in the economy.
As an example, McCarthy mentioned General Electric Co., which said that its healthcare division reported a 17% drop in revenue in early April primarily on lower sales of imaging devices to community hospitals.
“Smaller drug and device companies with less diversified product lines may experience more severe revenue and profit swings,” McCarthy said.
McCarthy also mentioned “Wall Street” factors, including investors’ interest in stocks that are likely to show price improvement this year—something that may not match with the longer timeline that smaller drug and device companies typically follow to get their products approved and to market.
But some local companies are garnering investors’ attention.
Irvine-based Spectrum Pharmaceuticals Inc. said last week that the drug candidate ozarelix, which would be used to treat enlarged prostates, showed sufficient activity to warrant continued development despite its initial trial failure.
And Peregrine Pharmaceuticals Inc. of Tustin is working on cancer development drugs. Peregrine officials declined an interview request.
Smaller drug companies are at “the mercy of the markets and they’re at the mercy of their FDA results. But if they have a good story, they’re able to go back and continue to raise more capital,” said Terrance McGovern, managing partner of Crystal Cove Capital LLC, a healthcare investment banker in Irvine.
Some of OC’s smaller drug makers have raised money in “follow-on” stock offerings. A recent example is Avanir Pharmaceuticals Inc., an Aliso Viejo drug maker that completed a $40 million sale of stock to its investors earlier this month.
Avanir’s using the money raised from that offering to fund a clinical trial of its Zenvia drug candidate to treat involuntary emotional expression disorder, which is marked by bouts of uncontrollable crying or laughing.
Such stock sales allow smaller drug and device companies to stay in business despite losing money from low stock prices, McGovern said.
That pattern can continue as long as companies show continued progress at the clinical trial level, McGovern said.
But if clinical trials hit a delay or if results are indeterminate, a deal or a joint venture could become more attractive to a smaller public drug maker because “none of these companies have the same type of distribution and regulatory capabilities that major pharma has,” McGovern said.
“Even in phase three, the chances are still only 65% to 75% that the drug will actually get into production,” McGovern said.
But McCarthy said that if a small drug and device company has to raise capital, “It may be viewed as dilutive to shareholders.” That naturally prompts questions, he said, of whether shareholders would benefit more from a sale rather than what he called “another dilutive financing round.”
Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the second quarter of fiscal year 2008 on December 10, 2007 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.
Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.
The conference call and webcast will begin at 11:30 a.m. EST/8:30 a.m. PST.
To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.
To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2007 by calling (877) 344-7529, passcode 382933#.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Contacts:
GendeLLindheim BioCom Partners
Investors Media
info@peregrineinc.com Barbara Lindheim
(800) 987-8256 (212) 918-4650
SOURCE Peregrine Pharmaceuticals, Inc.
-0- 12/03/2007
/CONTACT: Investors, 1-800-987-8256, info@peregrineinc.com, or Media,
Barbara Lindheim of GendeLLindheim BioCom Partners, +1-212-918-4650, for
Peregrine Pharmaceuticals, Inc./
/Web site: http://www.peregrineinc.com
http://www.avidbio.com /
(PPHM)
CO: Peregrine Pharmaceuticals, Inc.
ST: California
IN: HEA BIO
SU: CCA
MW-SO
-- LAM024 --
5423 12/03/2007 08:00 EST http://www.prnewswire.com
Science Daily article:
Mark :)
http://www.sciencedaily.com/releases/2007/09/070901073606.htm
Source: UT Southwestern Medical Center
Date: September 2, 2007
More on:
Lung Cancer, Brain Tumor, Cancer, Colon Cancer, Prostate Cancer, Breast Cancer
Radiation And Drug Combo Helps Boost Efficacy Of Lung Cancer Treatment
Science Daily — Combining radiation therapy with a drug that helps destroy blood vessels nourishing malignant tumors has been shown in mice to be significantly more effective in treating lung cancer than either approach alone, researchers at UT Southwestern Medical Center have found.
The study, involving human lung-cancer cells implanted in mice, appears in the Sept. 1 issue of Clinical Cancer Research.
In the study, Dr. Philip Thorpe, professor of pharmacology at UT Southwestern, and his colleagues found that radiation generates a chemical reaction in the membranes of endothelial cells, which line the blood vessels that feed tumors. The reaction causes membrane components called anionic phospholipids to flip inside out, exposing them. In normal blood vessels, they face the interior of the cell.
Dr. Thorpe's previous research has shown that anionic phospholipids, particularly one called phosphatidylserine, are already flipped inside-out on tumor endothelial cells.
"The flipping is likely due to stress conditions present in the tumor micro-environment, and radiation increases the number of exposed phospholipids," said Dr. Thorpe.
Once they induced more flipping with radiation, the researchers administered bavituximab, a monoclonal antibody that homes in on tumor vessels by selectively binding to the inside out phospholipids. The binding signals white blood cells from the immune system to attack and destroy the vessels feeding the tumor.
In their study of mice, the researchers found that radiation increased the percentage of phospholipids that flip inside out from 4 percent to 26 percent. Treating the mice with bavituximab and radiation therapy together reduced tumor growth by 80 percent and was more effective than administering either treatment by itself.
"About 30 percent of all lung-cancer patients receive radiation and, in this animal model of lung cancer, we found that this monoclonal anitbody improves the efficacy of radiation therapy without the toxicity seen in other chemotherapeutic drugs," said Dr. Thorpe. "It's a win-win."
Bavituximab was created in Dr. Thorpe's lab is currently being tested in clinical trials in the U.S. and India for its effectiveness against solid-tumor cancers.
Peregrine Pharmaceuticals Inc. has exclusively licensed bavituximab from UT Southwestern and has a sponsored research agreement to further explore clinical uses of the drug. Dr. Thorpe is a consultant to and has an equity interest in the company.
Lung cancer is the leading cause of cancer death in the U.S. About 213,000 cases of lung cancer will be diagnosed this year and 160,000 people are expected to die from the disease, according to the National Cancer Institute. "Although there are current therapies, the five-year survival rate for lung-cancer patients remains at only 15 percent,"
Dr. Thorpe said. "This tells us that there is an urgent need to develop new treatment strategies." Vascular targeting agents such as bavituximab kill tumors without causing damage to surrounding healthy tissue. They cause fewer side effects than conventional cancer drugs that kill rapidly dividing normal cells along with the cancer cells.
Because Peregrine is already testing bavituximab in cancer patients, Dr. Thorpe said he expects new clinical trials using a combination of bavituximab and radiation therapy to start soon.
Note: This story has been adapted from a news release issued by UT Southwestern Medical Center.
Many thanks Sunstar, much appreciated...
Mark :)
Sunstar....
"BP is not going to offer full value with less than 100 bavi patients treated so far. "
Are you saying that 100 or more patients must be treated with Bavi before there is significant interest from BP? Does the 100 patient number include total patients treated (i.e. phase I, phase II), or just patients in phase II?
Many thanks for your response.
Mark :)
I'd put the odds a little higher Furter, say like 95% -- I willing to bet that they work through and resolve any issues with the final contract....
Mark :)
Hello all, here is a link to a video about DITRA (Defense Threat Reduction Agency).
http://www.dtra.mil/documents/about/DTRAVideo.wmv
Mark :)
Thanks jazz.. I'm sitting on pins and needles waiting on the data to come in from cancer and av bavi indications. Once it does, can't see the pps being held down at these levels..
Mark :)
Goat, from what I can recall, all mice in control group died within days. Mice treated w/bavi, all mice were near death, bavi cured half of the mice. Surviving mice were re-injected with leathal dose of lassa virus at 6 months (??), and mice stayed healthy with no signs of virus, indicating that bavi helped build an immunity to the virus. Is this correct?
Mark :)
Hey IT, thanks for your efforts to translate that page. I thought it was Chinese but it could have been Japanese.
Mark :)
Can anyone translate this page? A Chinese blog that discusses Bavi but I can't get a good translation...
http://homepage.infotopjp.com/2007/01/071.php
Mark :)
My apologies if this has already been posted...
Mark :)
LINK: http://medicalethics.suite101.com/article.cfm/DODsWaronBreastCancer
DOD’s War on Breast Cancer© Tom J. Donohue
The U.S. Defense Department authorizes a research grant for the fight against a disease that terrorizes American women, metastatic breast cancer.
The Department of Defense (DOD) has come under intense criticism, along with the White House, for its brain-dead policies in managing the war in Iraq.
At the same time, however, the DOD shows some innovative thinking and strategic insight in another war fought here in the homeland: the war against metastatic breast cancer, which kills approximately 40,000 American women each year.
The DOD's assault against breast cancer is being waged under the legal authority of the Congressional Special Interest Medical Research Programs (CSI). Since 1992, these programs have administered approximately $3.4 billion in various peer-review research projects aimed at preventing or curing a multitude of diseases.
Most recently, the DOD awarded the University of Texas Southwestern Medical Center a $460,000 grant to study a cutting-edge new cancer drug named bavituximab, formerly known as Tarvacin, which is being developed by Tustin, Calif.-based Peregrine Pharmaceuticals, Inc.
Perhaps, what the DOD likes about the bavituximab compound is its capacity for precise targeting of the enemy (in this case, it targets breast cancer cells that metastasize, or spread, throughout a woman's body). And thus, bavituximab's precise targeting also has the potential to lower the risk for collateral damage to the body's non-cancer cells.
The University of Texas proposes to study the efficacy of bavituximab on two levels: to study it on the diagnostic level as an imaging agent, and to study it on the therapeutic level as an agent that kills off the blood supply of tumors (and thereby prevents the cancer from spreading throughout the body).
Bavituximab is a monoclonal antibody that binds to specific cells that line tumor blood vessels. More specifically, it binds to a compound called phospholipids, which appear on the outer surface of cancer cells, but on the inside of normal cells.
By binding with the phospholipids of those malignant cells, bavituximab exercises a therapeutic effect by preventing those abnormal cells from developing their blood supply, which they require to sustain tumor growth, while leaving normal cells unscathed and still able to thrive.
On the diagnostic level, researchers hope to link bavituximab to an isotope to form a radioimmunoconjugate. An immunoconjugate is a complex of an antibody and a toxic agent (as a radiation drug) used to kill cancer cells; and in the case of its "radio" component, it would add an imaging attribute that would allow clinicians to see where the cancer is spreading.
"Data from this project could open the door for use of bavituximab as an agent to identify, measure and ultimately destroy the metastases that kill most cancer patients," Steven W. King, president and CEO of Peregrine, said in an April 25, 2006, company press release. "We look forward to the results of these studies that will assess its utility as a new class of imaging and therapeutic agents for breast cancer."
Ralph Mason, Ph.D., a professor of radiology at the University of Texas Southwestern Medical Center and a principal investigator of the study, made the following statement, which appears in the same press release:
"This new DOD project will enable us to assess bavituximab's utility for both tumor detection and therapy in breast cancer. Since bavituximab's unique target is expressed on blood vessels in tumors but not normal tissues, it may have both safety and efficacy advantages compared to other antibodies. We are eager to assess the utility of a bavituximab radioimmunoconjugate for the identification and treatment of metastatic breast disease."
IT... maybe they think the SP is going up, thus less amount of shares needed to file for the $30 mil??
Mark :)
< Even more mysterious to me, after all of management's
investment conference presentations, is: "Why weren't
there more investment firms in on the CC?" >
Is it possible that there were investment firms on the call
in "listen mode" and not asking questions? Possibly there questions already anwered.....
Mark :)